KH903 is a novel antiangiogenic drug for cancer therapy. Its pharmacokinetic study in cancer patients is therefore very important for choosing doses and dosing intervals in clinical application. A selective, sensitive, and rapid Enzyme-Linked Immunosorbent Assay (ELISA) method was developed and validated here for the determination of KH903 in patient serum. This method is specific enough for the detection of KH903 in serum samples. Nonlinear calibration curves were obtained for KH903 at a concentration range of 0.781-50 ng/ ml (r > 0.999). The intra-batch accuracy ranged from 83.4% to 94.5%, and the inter-batch accuracy varied from 88.8% to 91.7%. Stability tests showed that KH903 was stable throughout the analytical procedure. This study is the first to utilize the ELISA method for the pharmacokinetic study of KH903 in six cancer patients who had received a single dose of KH903 (4.0 mg/ kg) administered intravenously. The results address the pharmacokinetic profile of KH903 in cancer patients in detail and evaluate the binding efficacy of KH903 on VEGF in patients to provide guidance for the regimen of KH903 in phase I clinical trials. You can submit your Manuscripts at: https://symbiosisonlinepublishing.com/submitManuscript.php
Comments: 6 Pages.
[v1] 2017-08-28 02:24:17
Unique-IP document downloads: 43 times
Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.
Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.